Acceder

Farmas USA

135K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
11.076 / 16.996
#88602

Re: Farmas USA

NVAX

Escalando otra vez.

"Buf, se me está haciendo más largo que un dia sin bolsa"

#88603

Re: Farmas USA

PTCT ya ha roto los 8 pavos.

PTX,0,47,,todavia ando pillado a 0,49.

TTPH poco a poco ya esta en 4,25.

La unica analista de la que me fio y sigo es .....la portera de mi casa.

#88604

Re: Farmas USA

Estoy en verdeeeeeeeeee!!! Oeoeoeoeoeoe!!!
NVAX

#88605

Re: Farmas USA

Nvax
A mí solo me falta un pavo
!!biennnnnn!! Jajaja

#88606

Re: Farmas USA

http://247wallst.com/healthcare-business/2016/05/23/10-speculative-biotech-and-biohealth-stocks-with-massive-analyst-upside-calls/

Amarin

Amarin Corp. (NASDAQ: AMRN) was assumed with a Buy rating and a $3.50 price target (versus a $1.57 prior close) at Jefferies on May 12. The firm said it believes that the off-label Vascepa promotion in mixed dyslipidemia may be starting to bear fruit. It said:

We believe off-label Vascepa promotion in mixed dyslipidemia may be beginning to bear fruit, where our analysis of TRx data suggests a steeper upward trend in recent months v. 2015. Access to this population is a major source of upside, where we see opportunity of $2.5 billion. Focus is also on REDUCE-IT where we believe Vascepa can show a benefit on final analysis in early 2018, and upside could be $14 per share.

Read more: 10 Speculative Biotech and Biohealth Stocks With Massive Analyst Upside Calls - Amarin Corp plc (ADR) (NASDAQ:AMRN) - 24/7 Wall St. http://247wallst.com/healthcare-business/2016/05/23/10-speculative-biotech-and-biohealth-stocks-with-massive-analyst-upside-calls/#ixzz49bHOVIGF
Follow us: @247wallst on Twitter | 247wallst on Facebook

#88608

Re: Farmas USA

Que aguanten, que aguanten que mañana vendrá el mini tsunami con Stan

Nvax

Te puede interesar...
  1. Tech insostenible, Wall Street confía en la rotación sectorial
  2. Valoraciones, expectativas de beneficios y “Pain Trade”.
  3. Carteras Crecimiento y Conservador. MAYO 2024.
  1. Tech insostenible, Wall Street confía en la rotación sectorial
  2. Valoraciones, expectativas de beneficios y “Pain Trade”.
Brokers destacados